The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2025 | Managing cytokine release syndrome in T-cell engager therapies for small cell lung cancer
Anna Minchom, MD, BCh, MB, MRCP, The Royal Marsden Hospital, London, UK, discusses the management of cytokine release syndrome (CRS), a key challenge associated with emerging T-cell engager therapies for small cell lung cancer. She highlights the need for oncologists to become more familiar with treatments like tocilizumab and emphasizes the importance of educating hospital teams on recognizing and managing CRS effectively. This interview took place at the BTOG 2025 congress in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
